D'Orazio & Associates’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $580K | Sell |
24,083
-3,063
| -11% | -$80.1K | 0.07% | 115 |
|
|
2026
Q1 | $762K | Buy |
27,146
+636
| +2% | +$16.9K | 0.1% | 79 |
|
|
2025
Q4 | $660K | Buy |
26,510
+12,622
| +91% | +$318K | 0.08% | 90 |
|
|
2025
Q3 | $354K | Buy |
13,888
+3,998
| +40% | +$98.7K | 0.05% | 153 |
|
|
2025
Q2 | $240K | Buy |
9,890
+1,060
| +12% | +$24.7K | 0.03% | 221 |
|
|
2025
Q1 | $224K | Buy |
8,830
+1,281
| +17% | +$33.5K | 0.03% | 214 |
|
|
2024
Q4 | $200K | Buy |
7,549
+391
| +5% | +$10.6K | 0.03% | 225 |
|
|
2024
Q3 | $207K | Sell |
7,158
-389
| -5% | -$11.3K | 0.03% | 217 |
|
|
2024
Q2 | $211K | Sell |
7,547
-84
| -1% | -$2.31K | 0.03% | 189 |
|
|
2024
Q1 | $212K | Sell |
7,631
-242
| -3% | -$6.71K | 0.03% | 174 |
|
|
2023
Q4 | $227K | Sell |
7,873
-663
| -8% | -$20K | 0.04% | 145 |
|
|
2023
Q3 | $283K | Sell |
8,536
-1,416
| -14% | -$50.1K | 0.06% | 100 |
|
|
2023
Q2 | $365K | Buy |
9,952
+3,653
| +58% | +$142K | 0.09% | 88 |
|
|
2023
Q1 | $257K | Sell |
6,299
-2,133
| -25% | -$92.1K | 0.07% | 102 |
|
|
2022
Q4 | $432K | Sell |
8,432
-2,268
| -21% | -$109K | 0.1% | 73 |
|
|
2022
Q3 | $468K | Buy |
10,700
+1,479
| +16% | +$71.9K | 0.14% | 59 |
|
|
2022
Q2 | $483K | Buy |
9,221
+1,042
| +13% | +$53.1K | 0.13% | 54 |
|
|
2022
Q1 | $423K | Buy |
8,179
+465
| +6% | +$24.1K | 0.1% | 59 |
|
|
2021
Q4 | $456K | Buy |
7,714
+939
| +14% | +$46.5K | 0.11% | 54 |
|
|
2021
Q3 | $291K | Buy |
6,775
+542
| +9% | +$24K | 0.07% | 71 |
|
|
2021
Q2 | $244K | Buy |
6,233
+718
| +13% | +$27.9K | 0.06% | 73 |
|
|
2021
Q1 | $200K | Sell |
5,515
-249
| -4% | -$8.84K | 0.06% | 80 |
|
|
2020
Q4 | $212K | Sell |
5,764
-406
| -7% | -$14.9K | 0.07% | 70 |
|
|
2020
Q3 | $215K | Buy |
6,170
+171
| +3% | +$6K | 0.09% | 66 |
|
|
2020
Q2 | $186K | Buy |
5,999
+16
| +0.3% | +$544 | 0.08% | 66 |
|
|
2020
Q1 | $185K | Sell |
5,983
-2,823
| -32% | -$96.2K | 0.09% | 59 |
|
|
2019
Q4 | $327K | Buy |
8,806
+31
| +0.4% | +$1.1K | 0.1% | 51 |
|
|
2019
Q3 | $299K | Buy |
8,775
+434
| +5% | +$15.8K | 0.1% | 50 |
|
|
2019
Q2 | $343K | Sell |
8,341
-144
| -2% | -$5.72K | 0.1% | 45 |
|
|
2019
Q1 | $342K | Buy |
8,485
+198
| +2% | +$7.93K | 0.1% | 42 |
|
|
2018
Q4 | $343K | Buy |
8,287
+1,076
| +15% | +$44.7K | 0.11% | 33 |
|
|
2018
Q3 | $302K | Buy |
7,211
+26
| +0.4% | +$1K | 0.11% | 46 |
|
|
2018
Q2 | $247K | Sell |
7,185
-78
| -1% | -$2.67K | 0.09% | 46 |
|
|
2018
Q1 | $245K | Buy |
7,263
+138
| +2% | +$4.74K | 0.09% | 43 |
|
|
2017
Q4 | $245K | Buy |
7,125
+1,214
| +21% | +$41.4K | 0.09% | 48 |
|
|
2017
Q3 | $200K | Sell |
5,911
-708
| -11% | -$22.8K | 0.07% | 51 |
|
|
2017
Q2 | $211K | Buy |
6,619
+1,084
| +20% | +$34.2K | 0.08% | 48 |
|
|
2017
Q1 | $180K | Buy |
5,535
+30
| +0.5% | +$946 | 0.07% | 49 |
|
|
2016
Q4 | $170K | Buy |
5,505
+29
| +0.5% | +$885 | 0.07% | 48 |
|
|
2016
Q3 | $175K | Buy |
5,476
+25
| +0.5% | +$836 | 0.07% | 49 |
|
|
2016
Q2 | $182K | Buy |
5,451
+88
| +2% | +$2.81K | 0.07% | 50 |
|
|
2016
Q1 | $150K | Buy |
5,363
+236
| +5% | +$6.74K | 0.06% | 59 |
|
|
2015
Q4 | $157K | Buy |
5,127
+2,003
| +64% | +$63K | 0.08% | 46 |
|
|
2015
Q3 | $101K | Buy |
3,124
+274
| +10% | +$8.79K | 0.05% | 65 |
|
|
2015
Q2 | $91K | Buy |
2,850
+3
| +0.1% | +$98 | 0.06% | 64 |
|
|
2015
Q1 | $94K | Buy |
2,847
+4
| +0.1% | +$127 | 0.07% | 64 |
|
|
2014
Q4 | $84K | Sell |
2,843
-249
| -8% | -$7.14K | 0.06% | 63 |
|
|
2014
Q3 | $87K | Buy |
3,092
+4
| +0.1% | +$112 | 0.06% | 60 |
|
|
2014
Q2 | $87K | Buy |
3,088
+3
| +0.1% | +$86 | 0.07% | 57 |
|
|
2014
Q1 | $94K | Buy |
3,085
+4
| +0.1% | +$119 | 0.07% | 53 |
|
|
2013
Q4 | $90K | Buy |
+3,081
| New | +$89.7K | 0.08% | 50 |
|
Other funds holding PFE
D'Orazio & Associates's PFE Position: Q2 2026 in Review
D'Orazio & Associates reduced its Pfizer (PFE) stake by 11% in Q2 2026, selling an estimated $80.1K and leaving 24,083 shares worth $580K. The position accounts for 0.07% of the portfolio, ranked #115.
D'Orazio & Associates first reported a position in PFE in Q4 2013 and has held it in 51 quarters since. The position peaked at $762K in Q1 2026. 2,822 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- D'Orazio & Associates held 24,083 shares of Pfizer worth $580K as of Q2 2026.
- D'Orazio & Associates sold 3,063 Pfizer shares in Q2 2026, an estimated $80.1K.
- Pfizer made up 0.07% of D'Orazio & Associates's portfolio in Q2 2026, its #115 holding.
- D'Orazio & Associates first reported a position in Pfizer in Q4 2013 and has held it in 51 quarters since.
- D'Orazio & Associates's Pfizer position peaked at $762K in Q1 2026.
- 2,822 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on D'Orazio & Associates's 13F filing for Q2 2026, filed 28 Jul 2026.